Theodore A. Gobillot

Theodore A. Gobillot

Auto-generated profile, based on publicly available information

Theodore A. Gobillot

Department of Otorhinolaryngology‐Head & Neck Surgery University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2016 in ACS Chemical Biology
Verified
Journal Article
Closed access
HFHannah C. Feldman
Hannah C. Feldman
MTMichael Tong
Michael Tong
LWLikun Wang
Likun Wang
RMRosa Meza-Acevedo
Rosa Meza-Acevedo
TGTheodore A. Gobillot
Theodore A. Gobillot
DMDustin J. Maly
Dustin J. Maly

1 December 2014 in Chemistry & Biology
Verified
Journal Article
Closed access
MHMatthew K. Howe
Matthew K. Howe
KBKhaldon Bodoor
Khaldon Bodoor
DCDavid A. Carlson
David A. Carlson
PHPhilip F. Hughes
Philip F. Hughes
YAYazan Alwarawrah
Yazan Alwarawrah
THTimothy A.J. Haystead
Timothy A.J. Haystead

19 February 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
KWKatherine L. Williams
Katherine L. Williams
MSMegan Stumpf
Megan Stumpf
NNNicole Elise Naiman
Nicole Elise Naiman
SDShilei Ding
Shilei Ding
MGMeghan Garrett
Meghan Garrett
JOJulie Overbaugh
Julie Overbaugh
Antibodies that mediate killing of HIV-infected cells through antibody-dependent cellular cytotoxicity (ADCC) have been implicated in protection from HIV infection and disease progression. Despite these observations, these types of HIV antibodies are understudied compared to neutralizing antibodies. Here we describe four monoclonal antibodies (mAbs) obtained from one individual that target the HIV transmembrane protein, gp41, and mediate ADCC activity. These four mAbs arose from independent B cell lineages suggesting that in this individual, multiple B cell responses were induced by the gp41 antigen. Competition and phage peptide display mapping experiments suggested that two of the mAbs target epitopes in the cysteine loop that are highly conserved and a common target of HIV gp41-specific antibodies. The amino acid sequences that bind these mAbs are overlapping but distinct. The two other mAbs were competed by mAbs that target the C-terminal heptad repeat (CHR) and the fusion peptide proximal region (FPPR) and appear to both target a similar unique conformational epitope. These gp41-specific mAbs mediated killing of infected cells that express high levels of Env due to either pre-treatment with interferon or deletion of vpu to increase levels of BST-2/Tetherin. They also mediate killing of target cells coated with various forms of the gp41 protein, including full-length gp41, gp41 ectodomain or a mimetic of the gp41 stump. Unlike many ADCC mAbs that target HIV gp120, these gp41-mAbs are not dependent on Env structural changes associated with membrane-bound CD4 interaction. Overall, the characterization of these four new mAbs that target gp41 and mediate ADCC provides evidence for diverse gp41 B cell lineages with overlapping but distinct epitopes within an individual. Such antibodies that can target various forms of envelope protein could represent a common response to a relatively conserved HIV epitope for a vaccine. Anti-HIV antibodies can mediate activity by neutralizing cell-free virus, or binding to infected cells and driving antibody-dependent cellular cytotoxicity (ADCC). While numerous discovery efforts have identified and characterized neutralizing antibodies, much less is known about antibodies that mediate ADCC. Here we describe four new antibodies that target the gp41 transmembrane protein of the HIV envelope. Competition experiments and peptide mapping studies together helped narrow down the binding sites for the four antibodies to two conserved regions of the protein. One pair of antibodies targets a common epitope of gp41 while the other pair binds to a more complex discontinuous epitope. In vitro activity assays indicated that this second pair of antibodies could drive killing against cells coated with various forms of gp41, and both pairs of antibodies could drive killing of HIV-infected cells. Inducing these types of antibodies following vaccination may represent a more straightforward path to generating a consistent, functional response to a more conserved portion of the HIV envelope protein.

1 January 2020 in Journal of Medical Education and Curricular Development
Verified
Journal Article
Open access
PDF file
AGAlec W Gibson
Alec W Gibson
TGTheodore A Gobillot
Theodore A Gobillot
KWKevin Wang
Kevin Wang
ECElizabeth Conley
Elizabeth Conley
WCWendy Coard
Wendy Coard
CHCorinne Heinen
Corinne Heinen
Background: Lesbian, gay, bisexual, transgender, and queer (LGBTQ) individuals face considerable health disparities, often due to a lack of LGBTQ-competent care. Such disparities and lack of access to informed care are even more staggering in rural settings. As the state medical school for the Washington, Wyoming, Alaska, Montana, and Idaho (WWAMI) region, the University of Washington School of Medicine (UWSOM) is in a unique position to train future physicians to provide healthcare that meets the needs of LGBTQ patients both regionally and nationally. Objective: To describe our methodology of developing a student-driven longitudinal, region-wide curriculum to train medical students to provide high-quality care to LGBTQ patients. Methods: A 4-year LGBTQ Health Pathway was developed and implemented as a student-led initiative at the UWSOM. First- and second-year medical students at sites across the WWAMI region are eligible to apply. Accepted Pathway students complete a diverse set of pre-clinical and clinical components: online modules, didactic courses, longitudinal community service/advocacy work, a scholarly project, and a novel clinical clerkship in LGBTQ health developed specifically for this Pathway experience. Students who complete all requirements receive a certification of Pathway completion. This is incorporated into the Medical Student Performance Evaluation as part of residency applications. Results: The LGBTQ Health Pathway is currently in its fourth year. A total of 43 total students have enrolled, of whom 37.3% are based in the WWAMI region outside of Seattle. Pathway students have completed a variety of scholarly projects on LGBTQ topics, and over 1000 hours of community service/advocacy. The first cohort of 8 students graduated with a certificate of Pathway completion in spring 2020. Conclusions: The LGBTQ Health Pathway at UWSOM is a novel education program for motivated medical students across the 5-state WWAMI region. The diverse milestones, longitudinal nature of the program, focus on rural communities, and opportunities for student leadership are all strengths and unique aspects of this program. The Pathway curriculum and methodology described here serve as a model for student involvement and leadership in medical education. This program enables medical students to enhance their training in the care of LGBTQ patients and provides a unique educational opportunity for future physicians who strive to better serve LGBTQ populations.

2 May 2020 in Viruses
Verified
Journal Article
Open access
PDF file
TGTheodore A. Gobillot
Theodore A. Gobillot
DHDaryl Humes
Daryl Humes
ASAmit Sharma
Amit Sharma
CKCaroline Kikawa
Caroline Kikawa
JOJulie Overbaugh
Julie Overbaugh
Type-I interferon (IFN-I) is a major antiviral host response but its impact on Zika virus (ZIKV) replication is not well defined, particularly as it relates to different circulating strains. Interferon stimulated genes (ISGs) that inhibit ZIKV, such as IFITM3, have been identified largely using overexpression studies. Here, we tested whether diverse ZIKV strains differed in their susceptibility to IFN-I-mediated restriction and the contribution of IFITM3 to this restriction. We identified a robust IFN-I-mediated antiviral effect on ZIKV replication (>100-fold reduction) in A549 cells, a commonly used cell line to study ZIKV replication. The extent of inhibition depended on the IFN-I type and the virus strain tested. Viruses from the American pathogenic outbreak were more sensitive to IFNα (p = 0.049) and IFNβ (p = 0.09) than African-lineage strains, which have not been linked to severe pathogenesis. Knocking out IFITM3 expression did not dampen the IFN-I antiviral effect and only high overexpression of IFITM3 led to ZIKV inhibition. Moreover, IFITM3 expression levels in different cells were not associated with IFN-mediated ZIKV inhibition. Taken together, our findings indicate that there is a robust IFN-I-mediated antiviral effect on ZIKV infection, particularly for American viruses, that is not due to IFITM3. A549 cells, which are a commonly used cell line to study ZIKV replication, present an opportunity for the discovery of novel antiviral ISGs against ZIKV.

1 June 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
CSCassandra Simonich
Cassandra Simonich
MSMackenzie M. Shipley
Mackenzie M. Shipley
LDLaura Doepker
Laura Doepker
TGTheodore Gobillot
Theodore Gobillot
MGMeghan Garrett
Meghan Garrett
JOJulie Overbaugh
Julie Overbaugh
Increasing evidence suggests infants develop unique neutralizing antibody (nAb) responses to HIV compared to adults. Here, we dissected the nAb response of an infant whose virus is in clinical trials as a vaccine immunogen, with a goal of characterizing the broad responses in the infant to this antigen. We isolated 73 nAbs from infant BG505 and identified a large number of clonal families. Twenty-six antibodies neutralized tier 2 viruses—in some cases, viruses from the same clade as BG505, and in others, a different clade, although none showed notable breadth. Several nAbs demonstrated antibody-dependent cellular cytotoxicity activity and targeted the V3 loop. These findings suggest an impressive polyclonal response to HIV infection in infant BG505, adding to the growing evidence that the nAb response to HIV in infants is polyclonal—a desirable vaccine response to a rapidly evolving virus like HIV.